Buy Rating for Beyond Air Driven by Anticipated FDA Approval and Strategic Partnerships

JonesTrading analyst Justin Walsh has reiterated their bullish stance on XAIR stock, giving a Buy rating today.

Justin Walsh’s rating is based on the anticipated approval and subsequent market adoption of Beyond Air’s next-generation LungFit PH device. The company has submitted a PMA supplement application to the FDA for this device, which is expected to be approved in the first half of 2026. This new version of the LungFit PH is designed to be more compact, user-friendly, and suitable for transport, which could significantly enhance its market appeal.
Additionally, Beyond Air’s strategic partnerships and distribution agreements in Europe and the Middle East are expected to expand its market reach to over 25 countries. The collaboration with Vanderbilt University Medical Center aims to optimize the LungFit products and demonstrate their clinical benefits, further supporting the potential for increased adoption. Despite some adjustments in revenue estimates, these developments underpin the expectation of substantial revenue growth, justifying the Buy rating and the $1 price target.

In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $1.00 price target.